OAKLAND, Calif.–(BUSINESS WIRE)–Promaxo, Inc. (“Promaxo” or the “Company”), a medical imaging, robotics, and AI technology company, announced today publication of a favorable Key Opinion Leader review in the August 2021 Issue of The European Medical Journal Urology (EMJ Urology). In the article, “Office-Based, Point-of-Care, Low-Field MRI System to Guide Prostate Interventions: Recent Developments,” the authors conclude that the portability and ease of use of Promaxo’s single-sided low-field MRI system provides the option for early diagnosis of prostate cancer through targeted biopsy and treatment in physician offices using the transperineal approach. The new technology supports higher cancer detection rates, while the approach limits infection rates, enabling targeted biopsies and therapeutic applications.
Dr. Ashutosh K. Tewari, Professor and System Chair, Department of Urology and Director of Center of Excellence for Prostate Cancer at the Tisch Cancer Institute at the Icahn School of Medicine at Mount Sinai, New York and the senior author leading the EMJ Urology review said: “The smaller footprint of the Promaxo MRI system with relatively straightforward navigation and registration techniques, is ideal for office-based procedures and allows board certified urologists to perform prostate interventions in outpatient settings.”
“Our technology is specifically designed and developed to address the limitations of traditional MRI systems and to redefine the standard of care for prostate interventions. We are very pleased for the Promaxo MRI System to be featured in this month’s issue of The European Medical Journal Urology,” said Dr. Amit Vohra, Founder and CEO of Promaxo. “Inclusion in the Journal’s article validates our mission to favorably address the goals of Quadruple Aim and more importantly improve patient lives through high confidence and efficient diagnosis and interventions.”
The limitations of high-field MRI based systematic transrectal biopsy in outpatient or ambulatory centers, including its shortcomings in cancer detection rates, have led to the development of innovational magnet design, radiofrequency, and gradient technologies for Promaxo low-field MRI. The Promaxo MRI System is the first single-sided, low-field, and open MRI platform developed and cleared by the U.S. FDA for prostate interventions of target lesions under MRI guidance.
The review is available at EMJ Urology. Please visit: https://www.emjreviews.com/urology/journal/emj-urology-9-1-2021-j010121/.
About European Medical Journal
The European Medical Journal (EMJ), is an independent, open-access eJournal dedicated to delivering insights into ground-breaking changes, and advancements in medicine. Spanning eighteen therapeutic areas, including Urology, Innovations, Cardiology, Oncology, and more, each journal provides the latest medical congress highlights, abstract reviews, and peer-reviewed articles, with wide content selection.
About Promaxo, Inc.
Promaxo was founded by a team of entrepreneurs and healthcare innovators to develop a minimally-invasive and patient-centric MRI and robotic platform. Based in Oakland, California, and backed by over 90 patents, the Company’s mission is to improve lives through state-of-the-art medical imaging, robotics and AI capabilities. With a compact and adaptable MRI, Promaxo is redefining the standard of care by improving the quality and speed of patient diagnosis and interventions. The Company has formed numerous long-term and strategic partnerships with investor groups and corporation as it prepares to enter the US market.